Related Experiment Video
Updated: Jul 16, 2026
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
CD274/PD-L1 copy number gained malignant peripheral nerve sheath tumor: A case report and literature review
1Department of Pathology, College of Medicine, Kyung Hee University Hospital, Seoul, Korea.
Rationale:
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with a poor prognosis, particularly in metastatic cases. Traditional treatments have shown limited effectiveness, highlighting the need for innovative therapeutic approaches. This case report aims to emphasize the critical role of genomic profiling in identifying therapeutic targets, particularly immune checkpoint inhibitors, to improve treatment strategies for MPNST.
Patient Concerns:
An 82-year-old male presented with a long-standing history of MPNST, multiple recurrences, and a recent rapid enlargement of a mass in the right axillary region. The patient also reported a 10% weight loss over the last 6 months.
Diagnoses:
Comprehensive genomic profiling of the tumor revealed significant alterations, including CD274/PD-L1 amplification, CDKN2A loss, and TP53 mutation. These genetic findings were aligned with previous cases that responded favorably to immune checkpoint inhibitors.
Interventions:
Despite the potential for targeted immunotherapy, the patient's economic constraints prevented the initiation of immune checkpoint inhibitor therapy. The patient underwent multiple surgical interventions, including an above-elbow amputation.
Outcomes:
The patient experienced severe wound bleeding and a significant decline in general condition, requiring intensive care unit support. Given the poor prognosis and high surgical risks, the patient's caregivers opted for hospice care.
Lessons:
Genomic profiling identifies genetic alterations that could guide immune checkpoint inhibitor therapy, offering the promise of personalized treatment for MPNST patients. By highlighting the potential of genomic profiling, this case demonstrates the importance of integrating personalized immunotherapy into future treatment paradigms for MPNST.
Insights
Genomic profiling of malignant peripheral nerve sheath tumors (MPNSTs) identified targets for immune checkpoint inhibitors. This case highlights the potential of personalized immunotherapy for MPNST, despite treatment limitations.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with poor outcomes.
- Current treatments for MPNSTs have limited efficacy, necessitating novel therapeutic strategies.
Purpose of the Study:
- To underscore the importance of genomic profiling in identifying therapeutic targets for MPNST.
- To explore the potential of immune checkpoint inhibitors in MPNST treatment.
Main Methods:
- A case report of an 82-year-old male with recurrent MPNST.
- Comprehensive genomic profiling of the tumor was performed.
- Analysis of genetic alterations including CD274/PD-L1 amplification, CDKN2A loss, and TP53 mutation.
Main Results:
- Genomic profiling revealed actionable targets for immunotherapy.
- The patient faced economic barriers to receiving immune checkpoint inhibitor therapy.
- The patient underwent surgical intervention with complications and ultimately transitioned to hospice care.
Conclusions:
- Genomic profiling can guide personalized immunotherapy for MPNST.
- This case emphasizes the potential of integrating genomic data into MPNST treatment paradigms.
- Challenges in accessing targeted therapies were noted.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
